|
Sipuleucel-T Clinical Trials
2 actively recruiting trials across 2 locations
▼ -1 trial since June 2026
Also known as: APC 8015, APC-8015, APC8015, APC8015 Vaccine, PA2024 (PAP/GM-CSF)-Loaded Dendritic Cell Vaccine +3 more
Pipeline
Phase 1: 1Phase 2: 1
Top Sponsors
- Yale University1
- City of Hope Medical Center1
Indications
- Cancer2
- Metastatic Castration-Resistant Prostate Adenocarcinoma1
- Metastatic Castration-resistant Prostate Cancer1
- Stage IVB Prostate Cancer AJCC v81
Duarte, California1 trial
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1
New Haven, Connecticut1 trial
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Yale Cancer Center
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.